ConductScience.org, home

Trial · NCT04095104

Registered outcomes28

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryEnrollment Rate6 months(Number enrolled divided by number eligible) x 100
PrimaryDropout Rate24 monthsNumber who do not complete the study divided by number enrolled
PrimaryNumber of Participants Adherent to Study Drugs12 weeksPresence of amphetamine in the urine at any study visit
PrimaryFrequency of Adverse Events24 months
Unique adverse events documented prior to unblinding. Adverse events were elicited using a standardized checklist during study phone calls and in-person study visits, laboratory monitoring, review of systems, vitals, physical exam, and mood/suicidality assessment using validated instruments at every study visit.
SecondaryPercent BMI ChangeBaseline and 12 weeks(Baseline BMI - BMI at 12 weeks)/Baseline BMI x 100
SecondaryPercent Weight ChangeBaseline and 12 weeks(Baseline weight - weight at 12 weeks)/Baseline weight x 100
SecondaryChange in BMI Percent of the 95th%IleBaseline and 12 weeks(Baseline BMI % of the 95th%ile - BMI % of the 95th%ile at 12 weeks)
SecondaryChange in Heart RateBaseline and 12 weeks(Heart rate at baseline - Heart rate at 12 weeks)
SecondaryChange in Systolic Blood PressureBaseline and 12 weeksSystolic blood pressure at baseline - Systolic blood pressure at 12 weeks
SecondaryChange in Diastolic Blood PressureBaseline and 12 weeksDiastolic blood pressure at baseline - Diastolic blood pressure at 12 weeks
SecondaryChange in Total Cholesterol (mg/dL)Baseline and 12 weeksTotal cholesterol at baseline - Total cholesterol at 12 weeks
SecondaryChange in Triglycerides (mg/dL)Baseline and 12 weeksTriglycerides at baseline - Triglycerides at 12 weeks
SecondaryChange in LDL Cholesterol (mg/dL)Baseline and 12 weeksLDL at baseline - LDL at 12 weeks
SecondaryChange in HDL Cholesterol (mg/dL)Baseline and 12 weeksHDL at baseline - HDL at 12 weeks
SecondaryChange in Alanine Aminotransferase (ALT) (U/L)Baseline and 12 weeksALT at baseline - ALT at 12 weeks
SecondaryChange in Hemoglobin A1c (HbA1c) (%)Baseline and 12 weeksHbA1c at baseline - HbA1c at 12 weeks
SecondaryChange in % Fat MassBaseline and 12 weeks% Fat mass at baseline - %Fat mass at 12 weeks measured by DEXA
SecondaryChange in Resting Metabolic Rate (RMR)Baseline and 12 weeksRMR at baseline - RMR at 12 weeks measured by indirect calorimetry
SecondaryChange in Daily Kilocalorie IntakeBaseline and 12 weeksThe average kilocalorie intake of 3 days was calculated each at baseline and 12 weeks. Kilocalories were calculated based on a standardized self-reported log of two weekdays and 1 weekend day.
SecondaryChange in HungerBaseline and 12 weeks
The adolescent/young adult will report subjective hunger before each meal and snack for 24 hours using a visual analogue slider scale (0= no hunger, 100 = most hunger) and this score will be averaged over the 24 hour period.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04095104/registered